STL Volume 31 Number 5

Delgocitinib 2% cream is the first topical pan-JAK inhibitor approved for moderate-to-severe chronic hand dermatitis. This review covers its mechanism, phase 2 and DELTA 1–3 trial results, long-term safety without a boxed warning, and its role as a steroid-sparing option in clinical practice.

Mild hidradenitis suppurativa still has no approved treatments. This review covers emerging topical options for Hurley stage I disease, including ruxolitinib, roflumilast and clascoterone, plus new HS cleansers and a Catalytic Treatment Matrix for faster wound healing after surgical deroofing.

Update on dupilumab (Dupixent®), now FDA-approved for chronic spontaneous urticaria in children 2-11 years, and adapalene 0.1% + benzoyl peroxide 2.5% (Differin® Epiduo® Acne Gel), now OTC. Plus: bemotrizinol, the first new FDA sunscreen filter in 20+ years, and a Health Canada peptide warning.